Anebulo Pharmaceuticals Appoints Richie Cunningham as Chief Executive Officer

Anebulo Pharmaceuticals, a clinical-stage biopharmaceutical company focused on developing solutions for acute cannabinoid intoxication (ACI), has announced the appointment of Richie Cunningham as its new Chief Executive Officer. Cunningham will be replacing Simon Allen in this role.

Cunningham brings over 20 years of leadership experience in the biopharmaceutical industry, with expertise in drug discovery, commercialization, and launching therapies. He has a proven track record of success, having led companies through mergers, acquisitions, and licensing deals.

Commenting on his appointment, Cunningham expressed his excitement about the potential positive impact Anebulo can make in the lives of patients and the value it can bring to shareholders. He also emphasized his commitment to a values-driven culture.

Joseph F. Lawler, Founder and Chairman of Anebulo, highlighted Cunningham’s extensive experience in emerging biotech companies and his understanding of maximizing therapeutic lifecycles. Lawler believes Cunningham’s leadership will be instrumental as Anebulo prepares for the phase 3 development of its lead product candidate, ANEB-001.

ANEB-001 is a competitive antagonist at the human cannabinoid receptor type 1 (CB1) and has completed dosing in a Phase 2 clinical trial. The drug aims to block and reverse the negative effects of acute cannabinoid intoxication. Anebulo plans to initiate Phase 3 registrational studies for ANEB-001 in the first half of 2024.

Anebulo Pharmaceuticals is dedicated to developing novel solutions for people suffering from acute cannabinoid intoxication and substance abuse disorder. The company’s mission is to address the unmet medical need for a specific antidote for ACI.

For more information about Anebulo Pharmaceuticals and its lead product candidate, ANEB-001, please visit their website at www.anebulo.com.